August 18, 2023 Columns by John Connor Oh, how far we’ve come since the ‘Victorian Era’ of treating MS In 2010, I strolled into a new hospital to meet my new neurologist. In them there far-off days, I was indeed strolling ā nay, striding ā but it wouldn’t last. I was surrounded by an aura of self-confidence that anyone whoās survived the vicissitudes of nearly three decades of show…
December 5, 2022 News by Marisa Wexler, MS After Stabilizing Treatment, Disease Activity Predicts Outcome in Study Assessing disease activity from the first to second year after a diagnosis of multiple sclerosis (MS), once treatment has been initiated and stabilized, can help predict long-term disability outcomes. That’s according to the study, “Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term…
November 1, 2019 Columns by Ed Tobias My Lemtrada Journey: Observations at 18 Months After Round 2 It’s time for another update on how I’ve been doing with my Lemtrada (alemtuzumab) treatments. The bottom line is that I’m doing well. Lemtrada is a disease-modifying therapy (DMT) delivered in two stages. The first stage entails a series of five daily infusions, while the second stage involves…
June 17, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: DMT Strategy Study, MS and Genetic Mutations, MS Art Project, AI Helps Neuros Read MRIs DELIVER-MS Trial Recruiting RRMS Patients to Help Improve Treatment Decision-making What’s the best way to attack multiple sclerosis when it’s first diagnosed? Do you hit it hard and fast using the most effective disease-modifying therapy (DMT), or do you start with a lower efficacy DMT and slowly ramp up?…
March 4, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: New DMT, Stem Cell Trial, Pediatric MS Treatment Study FDA Will Review New Drug Application of Diroximel Fumarate for Relapsing Forms of MS The good news: Another disease-modifying therapy (DMT) has taken a step toward approval in the U.S. The discouraging news: It’s another DMT designed to treat relapsing forms of multiple sclerosis. More than a…
January 22, 2019 News by Jonathan Grinstein Certain Treatments Linked to Lower Risk of Secondary Progressive MS, Study Shows Initial treatment of relapsing-remitting multiple sclerosis (RRMS) with Gilenya (fingolimod), Tysabri (natalizumab), or Lemtrada (alemtuzumab) is associated with a lower risk of conversion to secondary progressive multiple sclerosis (SPMS), compared with interferon beta or Copaxone (glatiramer acetate), a study reports. Findings also showed that…